Salt and crystal form of egfr inhibitor, and composition and use thereof
US-2024352053-A1 · Oct 24, 2024 · US
Gold(I) complexes with anticancer properties and methods of use thereof
US10092579B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10092579-B2 |
| Application number | US-201715586333-A |
| Country | US |
| Kind code | B2 |
| Filing date | May 4, 2017 |
| Priority date | Jan 7, 2016 |
| Publication date | Oct 9, 2018 |
| Grant date | Oct 9, 2018 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Monomeric and dimeric gold(I) complexes as anticancer agents. The gold(I) complexes are coordinated to mixed ligands: one phosphine-based ligand that may be monodentate or bidentate and at least one dithiocarbamate-based ligand that is monodentate. Pharmaceutical compositions incorporating the gold(I) complexes, methods of synthesis, methods of treating cancer and methods of inhibiting cancer cell proliferation and inducing cancer cell apoptosis are also provided.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method for inhibiting proliferation of prostate cancer cells, comprising: contacting the prostate cancer cells with a cytotoxic effective amount of a gold(I) complex represented by Formula (3), wherein Formula (3) is: 2. The method of claim 1 , wherein the prostate cancer cells are human cells. 3. The method of claim 1 , wherein the cytotoxic effective amount of the gold(I) complex is from 5 to 50 μM. 4. The method of claim 1 , wherein the gold(I) complex exhibits an IC 50 of from 1 to 150 μM for inhibiting the proliferation and inducing the apoptosis of the prostate cancer cells. 5. The method of claim 1 , wherein the prostate cancer cells are at least one selected from the group consisting of PC-3 cells and DU-145 cells.
Assignees
Inventors
Classifications
ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine · CPC title
Complexes or chelates of phosphines with metallic compounds or metals · CPC title
Heavy metals; Compounds thereof · CPC title
- A61K31/66Primary
Phosphorus compounds · CPC title
Antibodies (agglutinins A61K38/36 {; as drug carriers A61K47/50}); Immunoglobulins; Immune serum, e.g. antilymphocytic serum · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10092579B2 cover?
- Monomeric and dimeric gold(I) complexes as anticancer agents. The gold(I) complexes are coordinated to mixed ligands: one phosphine-based ligand that may be monodentate or bidentate and at least one dithiocarbamate-based ligand that is monodentate. Pharmaceutical compositions incorporating the gold(I) complexes, methods of synthesis, methods of treating cancer and methods of inhibiting cancer c…
- Who is the assignee on this patent?
- Univ King Fahd Pet & Minerals
- What technology area does this patent fall under?
- Primary CPC classification A61K31/66. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Oct 09 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).